NEW YORK--(BUSINESS WIRE)--BTIG, LLC announced today that it will host the “BTIG Fall Biotechnology Conference” with featured panelists from emerging private and established multinational biotechnology companies. The format of the conference includes one-on-one meetings and panel discussions led by key opinion leaders and BTIG Biotechnology Analysts Tim Chiang, Robert Hazlett, Amanda Murphy, CFA and Thomas Shrader, PhD, CFA. The event will take place on Thursday, October 25th in New York.
The private conference is open to BTIG’s institutional investor clients and will cover key issues that impact biotechnology companies today. Panel discussion topics include New Treatments in Duchenne Muscular Dystrophy / Limb-Girdle Muscular Dystrophy; Gene Therapy: The Next Wave of Innovation; Targeted Oncology Therapies: Material Advancements, Intriguing Potential; Immuno-Oncology in Solid Tumors: What’s After PD1s?; Immuno-Oncology in Liquid Tumors: Where is the Unmet Need?; Therapeutic Advancements for CNS Disorders; and Topics in Metabolic Diseases: from T2D to Anemia and NASH.
“The biotechnology conference will exhibit some of the latest in scientific investigations, new technologies and therapeutic advancements,” commented David Lenchus, Director of Research at BTIG. “Our team of equity analysts have collaborated with BTIG Corporate Access to produce a thematic conference featuring some of the world’s most prominent thought leaders in the sector.”
BTIG’s Corporate Access program hosts client events across the consumer, energy, financials, healthcare, real estate, shipping and technology, media and telecommunications sectors.
For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend the event.
To access BTIG insights, contact a BTIG representative or visit www.btigresearch.com.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 600 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit www.btig.com.